Summative Usability Study of Ciprofloxacin Dry Powder for Inhalation Using Placebo
NCT ID: NCT02661438
Last Updated: 2018-12-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
46 participants
INTERVENTIONAL
2016-01-12
2016-03-17
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo to Ciprofloxacin DPI
Placebo to Ciprofloxacin DPI, 3 doses during test session, 1 additional dose for patients during device training
Placebo to Ciprofloxacin DPI (BAYQ3939)
Placebo to Ciprofloxacin DPI, 3 doses during test session, 1 additional dose for patients during device training
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Placebo to Ciprofloxacin DPI (BAYQ3939)
Placebo to Ciprofloxacin DPI, 3 doses during test session, 1 additional dose for patients during device training
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subjects must be aged ≥40
* Subject must be able to independently manage and administer their NCFB/COPD medications
Exclusion Criteria
* Subjects with recent significant hemoptysis in the four weeks before screening (and/or during the screening period)
* Subjects allergic to quinine
* Known chronic bronchial asthma
40 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novartis
INDUSTRY
Bayer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bayer Study Director
Role: STUDY_DIRECTOR
Bayer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Vero Beach, Florida, United States
Jamaica, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
18253
Identifier Type: -
Identifier Source: org_study_id